Rossari Biotech Limited (ROSSARI) — Corporate Action
Rossari Biotech approved Q1 FY2026 unaudited results, 4,000 stock options under its 2019 ESOP, and allotted 2,500 shares (Rs. 2 face value) raising paid-up capital to Rs. 11,07,88,232. It also proposed transferring 100% of Rossari International Limited to its Singapore subsidiary for Rs. 24 crores, pending Saudi approval by March 31, 2027. The filing includes auditor review of Q1 results and regulatory compliance details.
About Rossari Biotech Limited (ROSSARI)
Chemicals · Chemicals & Petrochemicals · Listed on NSE
📡 Get AI alerts when ROSSARI files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ROSSARI — Free💡 Ask AI about this filing
📊 More ROSSARI filings
- 🔴 Financial Results — 19 July 2026 Rossari Biotech reported record Q1 FY27 revenue of ₹697.2 crores, up 28.2% YoY, driven by strong per...
- 🔴 Financial Results — 19 July 2026 Rossari Biotech reported consolidated revenue of Rs. 697.2 crore for Q1 FY27, up 28% YoY, with EBITD...
- 🔴 Financial Results — 14 July 2026 Rossari Biotech announced its Q1 FY27 earnings conference call scheduled for July 20, 2026 at 5:00 P...
- 🔴 Annual Report — 27 June 2026 Rossari Biotech Limited announced its 17th Annual General Meeting on July 20, 2026 at 11:00 AM IST v...
- 🔴 Annual Report — 27 June 2026 Rossari Biotech announced that its Integrated Annual Report for FY2025-26 is now accessible via ross...
🔥 Also filed on 18 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when ROSSARI files new disclosures
Track ROSSARI filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ROSSARI — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research